Tuesday July 17, 2018

69,000 babies born on New Year’s day in India: Unicef

0
//
89
69,000 babies born on New Year's day in India: Unicef
69,000 babies born on New Year's day in India: Unicef. wikimedia commons
Republish
Reprint
United Nations, Jan 2, 2018: The United Nations Children’s Fund (Unicef) has estimated that nearly 386,000 babies were born on New Year’s Day, with India heading the list with 69,070.
More than 90 percent of the births took place in less developed regions, reports Xinhua news agency.
The Unicef reported that globally over half the births were estimated to have taken place in nine countries: India (69,070), China (44,760), Nigeria (20,210), Pakistan (14,910), Indonesia(13,370), the US (11,280), the Democratic Republic of the Congo (9,400), Ethiopia (9,020) and Bangladesh (8,370).
Among those children, some will unfortunately not make it past their first day.
In 2016, an estimated 2,600 children died within the first 24 hours every day of the year. Unicef said that for almost two million newborns, their first week was also their last.
In all, 2.6 million children died before the end of their first month. Among them, more than 80 percent died from preventable and treatable causes such as premature birth, complications during delivery and infections like sepsis and pneumonia.
Over the past two decades, the world has seen unprecedented progress in child survival, halving the number of children worldwide who die before their fifth birthday to 5.6 million in 2016.
But despite these advances, there has been slower progress for newborns. Babies dying in the first month account for 46 percent of all deaths among children under five.
Next month, Unicef will launch “Every Child Alive,” a global campaign to demand and deliver affordable, quality health care solutions for every mother and newborn.
These solutions include a steady supply of clean water and electricity at health facilities, presence of a skilled health attendant during birth, disinfecting the umbilical cord, breastfeeding within the first hour after birth and skin-to-skin contact between the mother and child. (IANS)
Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)

Next Story